Alterity Therapeutics Limited, a development stage enterprise, has announced the cessation of a significant number of its securities. Specifically, 1,935,759,704 options, identified by the ASX security code ATHAAI and expiring on August 31, 2024, have ceased due to the expiry of the option without exercise or conversion. The cessation took place on August 31, 2024, and no consideration was paid by the entity for the cessation. Following this event, Alterity Therapeutics has updated its issued capital structure, which now comprises 5,320,336,118 ordinary fully paid shares and various classes of options with different expiry dates and exercise prices. The announcement was made on September 2, 2024, and is in accordance with the rules and regulations of the Securities Exchange Act of 1934. The company's issued capital information is crucial for investors as it affects the total market capitalization and share value.

Alterity Therapeutics Limited, a development stage enterprise, has announced the cessation of a significant number of its securities. Specifically, 1,935,759,704 options, identified by the ASX security code ATHAAI and expiring on August 31, 2024, have ceased due to the expiry of the option without exercise or conversion. The cessation took place on August 31, 2024, and no consideration was paid by the entity for the cessation. Following this event, Alterity Therapeutics has updated its issued capital structure, which now comprises 5,320,336,118 ordinary fully paid shares and various classes of options with different expiry dates and exercise prices. The announcement was made on September 2, 2024, and is in accordance with the rules and regulations of the Securities Exchange Act of 1934. The company's issued capital information is crucial for investors as it affects the total market capitalization and share value.